Navigation Links
HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
Date:11/23/2011

FRAMINGHAM, Mass. and SYDNEY, Nov. 23, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference at 11:30 a.m. EST on Wednesday, November 30, 2011. The conference is being held November 29-30, 2011 at The New York Palace in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... When looking at the types of people ... into one of two categories: those that have a weak appetite or those that have ... still want to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... 03, 2015 , ... Each year, the editors of Modern ... activists, corporate executives, entrepreneurs, health care professionals, and others have had the most ... magazine to tap the National League for Nursing’s outspoken CEO, Beverly Malone ...
(Date:9/2/2015)... ... 2015 , ... Healthegy, a leading producer of conferences, podcasts ... deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ) ... Larry Renfro, CEO of Optum, will deliver the morning address. In his post, ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... An international team of cancer specialists and imaging ... response to treatment//. The guidelines will provide clinicians ... clinical trials of lymphoma treatments and should facilitate ... guidelines developed by the International Harmonization Project (IHP) ...
... born to mothers who smoked during pregnancy may find ... study//. ,A recent animal research suggests that ... find it difficult to quit smoking. Duke University Medical ... to nicotine is known to alter areas of the ...
... insurance to around 1.2 million families below the poverty ... ,"We are aware of the health challenges and ... decided to provide health insurance to BPL families, and ... project this year," Kumaraswamy said in Ingalagi village in ...
... suffering from asthma compared to other methods of ... of different medicines. ,Although several ... clinical trials directly comparing them have not been ... ,For the first time, researchers in the Childhood ...
... Some obese have not looked up from their plate full of ... for the free obesity surgery.// ,Earlier, the government ... medical condition could get the obesity surgery done, free of cost. ... avail the free surgery offered by the government. ,People ...
... stress and depression,// may be associated with higher ... in turn are related to an increased risk for ... 22 issue of Archives of Internal Medicine, one of ... studies have linked psychosocial characteristics with cardiovascular disease and ...
Cached Medicine News:Health News:New Guidelines For Assessing Lymphoma Treatment 2Health News:New Guidelines For Assessing Lymphoma Treatment 3Health News:Quitting Not Easy for Smokers Born to Smoking Women 2Health News:Karnataka's Free Health Insurance to the Poor 2Health News:Psychosocial Factors Associated With Higher Levels of Inflammatory Markers 2
... With the increase in Endoscopic cases it is ... Monitor with the Surgical Light. This combination ... without having to adopt an uncomfortable pose. ... including the NUVO Monitoring System. As such ...
... This configuration offers all the performance of a ... perfectly for use in Outpatient Settings, Minor Procedure ... Mounting two single lights either side of the ... in a General OR when combining Flat Screen ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
Medicine Products: